Cervical cancer is a cancer that develops in the cells lining the cervix, the narrow lower end of the uterus that connects to the vagina. It is the fourth most common cancer in women worldwide, with an estimated 660,000 new cases and 350,000 deaths in 2022 alone. Nearly all cases are caused by persistent infection with certain strains of human papillomavirus (HPV), and the disease is largely preventable through vaccination and screening.
How HPV Leads to Cervical Cancer
HPV is extremely common. Most sexually active people will contract it at some point, and in the vast majority of cases, the immune system clears the virus on its own. Cervical cancer develops when high-risk HPV strains, particularly HPV 16 and HPV 18, establish infections that persist for years instead of resolving.
When a high-risk HPV infection persists, the virus can accidentally integrate its own DNA into the chromosomes of cervical cells. Once embedded, the virus produces two proteins that effectively disable the cell’s built-in safety mechanisms. One protein blocks a key tumor-suppressing gene, while the other drives cells to divide uncontrollably. Together, these proteins destabilize the cell’s chromosomes and set the stage for cancerous changes. This process is slow, typically unfolding over 10 to 20 years, which is why regular screening can catch precancerous changes long before they become dangerous.
Types of Cervical Cancer
Up to 9 out of 10 cervical cancers are squamous cell carcinomas, which develop from flat cells lining the outer part of the cervix. These cancers most often begin in the “transformation zone,” a small area where the outer cervix meets the inner cervical canal. This is the zone that Pap tests and HPV tests are designed to sample.
Most remaining cases are adenocarcinomas, which arise from the mucus-producing gland cells deeper inside the cervical canal. Because of their location, adenocarcinomas can sometimes be harder to detect on routine screening. Rarely, cervical cancers have features of both types.
Symptoms to Recognize
Early cervical cancer often produces no symptoms at all. This is a major reason screening matters so much. As the cancer grows, the most common signs include vaginal bleeding after sex, between periods, or after menopause. Periods that are heavier or last longer than usual can also be a signal. Some people notice a watery or bloody vaginal discharge that may be heavy and have an unusual odor. Pelvic pain or pain during intercourse can develop as the tumor advances.
These symptoms overlap with many non-cancerous conditions, but any persistent or unusual bleeding deserves prompt evaluation.
Risk Factors Beyond HPV
While HPV is the necessary trigger for nearly all cervical cancers, several other factors influence whether a persistent infection progresses to cancer. Smoking is one of the most significant. The risk increases the more a person smokes or is exposed to secondhand smoke, likely because tobacco byproducts damage cervical cell DNA and weaken the local immune response.
A weakened immune system also raises risk considerably. People living with HIV, those taking immunosuppressive medications after organ transplants, or those being treated for autoimmune conditions are less able to clear HPV infections, making progression to cancer more likely. Reproductive factors play a role as well: long-term use of oral contraceptives and having given birth to many children are both associated with higher cervical cancer risk, though the exact reasons remain unclear.
How Cervical Cancer Is Staged
Staging describes how far the cancer has spread and directly determines what treatment looks like. Cervical cancer uses the FIGO staging system, which runs from Stage I through Stage IV.
- Stage I: Cancer is confined entirely to the cervix. Substages distinguish between very small tumors visible only under a microscope (IA) and larger tumors up to or exceeding 4 cm (IB).
- Stage II: Cancer has grown beyond the cervix into the upper vagina or surrounding tissue, but hasn’t reached the pelvic wall or lower vagina.
- Stage III: Cancer has spread to the lower third of the vagina, the pelvic wall, or nearby lymph nodes. It may also be blocking a kidney.
- Stage IV: Cancer has spread to the bladder, rectum, or distant organs like the lungs or liver.
Treatment by Stage
For the earliest cancers (Stage IA), treatment can be as minimal as a cone-shaped surgical removal of the affected cervical tissue. This approach can preserve fertility. When the cancer has a higher risk of returning, a full hysterectomy with or without removal of the ovaries is typically recommended.
For Stage IA2 and some Stage IB cancers, treatment often involves a more extensive surgery that removes the cervix along with surrounding tissue and pelvic lymph nodes. A procedure called a radical trachelectomy removes the cervix while leaving the uterus intact, making future pregnancy possible for some patients.
Stages IB through IIA cancers are commonly treated with radiation combined with chemotherapy, or with radical surgery followed by radiation if the surgical findings suggest the cancer could recur. For Stage IIB and beyond, the standard approach is radiation delivered both externally and internally (a technique where a radiation source is placed near the tumor) alongside chemotherapy. Immunotherapy has become an additional option across several stages.
For Stage IVB or cancer that returns after initial treatment, immunotherapy drugs may be used alone or combined with chemotherapy and targeted therapy. In select cases where radiation isn’t an option, a major surgery called pelvic exenteration, which removes the affected pelvic organs, may be considered.
Survival Rates
Based on data from women diagnosed between 2015 and 2021, the five-year relative survival rate for cervical cancer caught while still localized to the cervix is 91%. When it has spread to nearby tissues or lymph nodes (regional), that rate drops to 62%. For cancer that has reached distant organs, the five-year survival rate is 20%. Across all stages combined, the overall five-year survival rate is 68%.
These numbers underscore how dramatically early detection changes outcomes. A cancer found through routine screening, before it causes symptoms, is far more likely to be localized and curable.
Prevention Through Vaccination and Screening
The HPV vaccine is the single most effective tool for preventing cervical cancer. In clinical trials, it showed over 90% efficacy against HPV infection, genital warts, and high-grade precancerous cervical changes in women without prior HPV exposure. Real-world effectiveness in young adolescents vaccinated between ages 9 and 14 ranges from roughly 74% to 93%.
Both the WHO and major U.S. medical organizations recommend starting HPV vaccination as early as age 9, ideally before any sexual activity begins. Children who start the series before age 15 need only two doses. Those who begin at 15 or older require three. Effectiveness drops when vaccination is delayed into the late teens, with real-world protection estimates falling as low as 12% to 90% for the 15-to-18 age group, depending on the outcome measured.
Screening with Pap tests and HPV tests catches precancerous changes years before they would become invasive cancer. Current guidelines generally recommend screening begin at age 21 or 25, depending on the test used, and continue at regular intervals through age 65. When precancerous cells are found, they can be removed with a simple outpatient procedure, effectively stopping cancer before it starts.
Global Disparities
About 94% of cervical cancer deaths in 2022 occurred in low- and middle-income countries, where access to HPV vaccination, screening, and treatment remains limited. In high-income countries with established screening programs, cervical cancer rates have dropped dramatically over the past several decades. The gap between these outcomes represents one of the starkest health inequities in cancer care today.